Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332439 | 0.89 | HTR1A (0.57) | HTR1AKDM4EPOLBHTR7ADRA1D | |
| SCHEMBL4318386 | 0.84 | ADRA1D (0.49) | HTR1AKDM4EPOLBLMNAADRA1D | |
| SCHEMBL4329767 | 0.82 | CHRNA7 (0.50) | HTR1AKDM4ETSHRHTR7KMT2A | |
| SCHEMBL4334275 | 0.81 | KDM4E (0.46) | HTR1AKDM4ELMNAHTR7ADRA1D | |
| SCHEMBL4339349 | 0.81 | DRD2 (0.43) | HTR1APOLBLMNAHTR7KMT2A | |
| SCHEMBL4330975 | 0.80 | KDM4E (0.47) | HTR1AKDM4ETSHRPOLBLMNA | |
| SCHEMBL4335940 | 0.80 | KDM4E (0.48) | HTR1AKDM4ETSHRPOLBLMNA | |
| SCHEMBL13913982 | 0.79 | KDM4E (0.47) | HTR1AKDM4ETSHRPOLBLMNA | |
| SCHEMBL4326476 | 0.79 | HTR1A (0.48) | HTR1AKDM4ETSHRHTR7MAPK1 | |
| SCHEMBL4471028 | 0.77 | HTR1A (0.57) | HTR1AKDM4EPOLBHTR7ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | HTR1A 38/4885KDM4E 3662/4885TSHR 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.